News & Events about Bluebird Bio Inc.
bluebird bio, Inc. (NASDAQ:BLUE Get Rating) has earned a consensus rating of Hold from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy ...
bluebird bio, Inc. (Nasdaq: BLUE) (bluebird) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a...
bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at...
bluebird bio, Inc. (NASDAQ: BLUE) (bluebird bio or the Company) today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million. bluebird bio was granted two PRVs upon the US Food and Drug Administration (FDA...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing, collaborations and mergers and acquisitions, financial...